<DOC>
	<DOCNO>NCT00516412</DOCNO>
	<brief_summary>RATIONALE : Everolimus may stop growth cancer cell block enzymes need cell growth . PURPOSE : This phase II trial study well everolimus work treat patient relapsed refractory mantle cell lymphoma .</brief_summary>
	<brief_title>Everolimus Treating Patients With Relapsed Refractory Mantle Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluation efficacy tolerability everolimus patient relapse therapy-resistant mantle cell lymphoma . Secondary - Evaluation efficacy everolimus induce molecular remission patient treat regimen . - Investigation immunoglobulin heavy chain variable gene somatic hypermutations ( Ig-V_H ) classical mantle cell lymphoma compare blastoid mantle cell lymphoma , particular regard frequency , mutation distribution pattern ( antigen select vs. random ) , individually involved Ig-V_H family . - Evaluation putative impact Ig-V_H clinical outcome . OUTLINE : This multicenter study . Patients receive oral everolimus daily day 1-28 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Bone marrow peripheral blood sample collect periodically analyzed molecular response PCR . Molecular study also perform DNA level formalin-fixed paraffin-embedded tissue sample . After completion study treatment , patient follow every 3 month 1 year , every 6 month 1 year , annually 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Inclusion criterion : Histologically cytologically confirm relapsed chemotherapy/immunotherapyresistant mantle cell lymphoma No 3 line prior systemic treatment At least one measurable lesion ≥ 15 mm great transverse diameter CT scan Exclusion criterion : Presence history CNS disease ( either CNS lymphoma lymphomatous meningosis ) Newly diagnose mantle cell lymphoma Patients suitable intensive treatment ( e.g. , hyperfractionated cyclophosphamide , vincristine , doxorubicin hydrochloride dexamethasone highdose methotrexate cytarabine [ HyperCVAD ] ) PATIENT CHARACTERISTICS : Inclusion criterion : WHO performance status ≤ 2 Creatinine clearance ≥ 30mL/min Bilirubin ≤ 2 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2 time ULN AST ALT ≤ 2 time ULN Neutrophils ≥ 1,500/mm³ ( ≥ 1,000/mm³ marrow infiltration ) Thrombocytes ≥ 100,000/mm³ ( ≥ 75,000/mm³ case bone marrow infiltration ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 12 month study participation Exclusion criterion : Prior concurrent hematological malignancy Patients prior solid organ tumor require treatment last 5 year currently free disease eligible Cardiovascular disease include follow : NYHA class III IV congestive heart failure Unstable angina pectoris Significant arrhythmia arrhythmia require chronic treatment Myocardial infarction last 3 month Serious underlie medical condition could impair ability patient participate trial include follow : Uncontrolled diabetes mellitus Gastric ulcer Active autoimmune disease Ongoing infection ( e.g. , HIV hepatitis ) PRIOR CONCURRENT THERAPY : Exclusion criterion : Prior radiation indicator lesion ( ) irradiate field Prior organ transplantation Participation another clinical trial within 30 day prior study entry Concurrent anticancer drugs/treatments experimental medication Other concurrent investigational therapy Other concurrent chemotherapy , immunotherapy , radiotherapy ( include palliative radiotherapy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
</DOC>